GLMD Galmed Pharmaceuticals Ltd.
$0.58 -2.85%
Healthcare · Pharmaceutical Preparations
Galmed Pharmaceuticals Ltd. (GLMD) is a healthcare company in the Pharmaceutical Preparations industry. Shares last traded at $0.58, 75.4% below their 52-week high. Over the past year the stock is down 58.0%.
Market Cap
—
Shares Out
—
EPS (TTM)
$2.39
P/E Ratio
0.24
P/S Ratio
—
P/B Ratio
—
Dividend / Share
—
Dividend Yield
—
52-Week High
$2.34
52-Week Low
$0.43
Volume
445
Avg Vol (3m)
114,021.905
Performance
1W
-11.46%
1M
-0.66%
3M
-5.50%
6M
-38.49%
YTD
-31.69%
1Y
-57.99%
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
RSI (14)
45.73
SMA (50)
$0.64
SMA (200)
$0.95
Price vs SMA50
-10.73%
Price vs SMA200
-39.34%
ATR (14)
$0.09
Financials
Revenue
$0M
Net Income
$-10M
Gross Margin
—
Operating Margin
—
Net Margin
—
Return on Equity
-65.3%
Return on Assets
-55.3%
Current Ratio
6.55
Debt / Equity
0.00
Revenue Growth (YoY)
—
Latest reported annual period ending 2020-12-31 · SEC EDGAR/XBRL.
Pharmaceutical Preparations peers
GLMD vs 14 industry peers (Pharmaceutical Preparations), by market cap.
1–14 of 14
| LLY | Lilly (Eli) | $1.04T | 50.16 | 15.88 | 31.7% | -1.17% |
| JNJ | Johnson & Johnson | $549.8B | 20.51 | 5.84 | 28.5% | -2.42% |
| ONC | Beone Medicines Ltd. | $390.6B | 1361.26 | 73.10 | 5.4% | +2.83% |
| ABBV | AbbVie | $382.5B | 90.51 | 6.25 | 6.9% | -2.16% |
| MRK | Merck | $281.6B | 15.43 | 4.33 | 28.1% | -1.30% |
| ABT | Abbott Laboratories | $154.3B | 23.65 | 3.48 | 14.7% | +0.09% |
| PFE | Pfizer | $143.7B | 18.50 | 2.30 | 12.4% | -2.89% |
| VRTX | Vertex Pharmaceuticals | $114.6B | 28.99 | 9.55 | 32.9% | -1.63% |
| BMY | Bristol Myers Squibb | $110.3B | 15.63 | 2.29 | 14.6% | -2.35% |
| REGN | Regeneron Pharmaceuticals | $63.4B | 14.08 | 4.42 | 31.4% | +0.38% |
| ALNY | Alnylam Pharmaceuticals | $36.9B | 117.57 | 9.93 | 8.4% | -1.66% |
| TEVA | Teva Pharmaceutical Industries Ltd | $36.6B | 25.98 | 2.12 | 8.2% | -3.33% |
| ZTS | Zoetis | $33.1B | 12.37 | 3.49 | 28.2% | +2.09% |
| RPRX | Royalty Pharma Plc | $23.1B | 30.02 | 9.73 | 32.4% | -1.30% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.